Does Rallies show Form 4 insider transactions for ZBIO?

Yes. Rallies tracks ZBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ZBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZBIO. It does not provide personalized investment advice.

ZBIO (Zenas BioPharma, Inc. Common Stock) Stock Analysis - Insider Trades

Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of May 19, 2026, ZBIO trades at $17.71 with a market cap of $1.16B and a P/E ratio of -1.38. ZBIO moved -7.96% today. Year to date, ZBIO is -50.99%; over the trailing twelve months it is +61.51%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $43.67. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ZBIO stock inside the company?

Recent ZBIO insider activity includes MOULDER LEON O JR bought 60.00K, MOULDER LEON O JR bought 35.00K, MOULDER LEON O JR bought 25.00K, Lu Hongbo bought 3.77K, and Fairmount Funds Management LLC bought 150.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ZBIO Key Metrics

Key financial metrics for ZBIO
Metric	Value
Price	$17.71
Market Cap	$1.16B
P/E Ratio	-1.38
EPS	$-11.89
Dividend Yield	0.00%
52-Week High	$44.60
52-Week Low	$5.83
Volume	1.13K
Avg Volume	0
Revenue (TTM)	$5.00M
Net Income	$-156.99M
Gross Margin	0.00%

Recent ZBIO Insider Trades

MOULDER LEON O JR bought 60.00K (~$1.01M) on May 18, 2026.
MOULDER LEON O JR bought 35.00K (~$616.70K) on Apr 29, 2026.
MOULDER LEON O JR bought 25.00K (~$450.50K) on Apr 28, 2026.
Lu Hongbo bought 3.77K (~$70.20K) on Mar 31, 2026.
Fairmount Funds Management LLC bought 150.00K (~$3.00M) on Mar 31, 2026.

Latest ZBIO News

Zenas BioPharma Grants 51,075 RSUs to New Hires, Vesting 2027–2030 — May 18, 2026
Zenas BioPharma Doses First Subject in Phase 1 Trial of Oral IL-17AA/AF Inhibitor — May 13, 2026
Zenas BioPharma Eyes FDA BLA After 56% IgG4-RD Flare Reduction, Cash to 2029 — May 13, 2026
Zenas BioPharma Secures $287.5M Net from $200M Convertible Notes and $100M Equity Offering — Mar 27, 2026
Zenas BioPharma Proposes 2032 Convertible Notes and Common Stock Offerings with 15% Option — Mar 26, 2026

ZBIO Analyst Consensus

6 analysts cover ZBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $43.67.

Common questions about ZBIO

Who is trading ZBIO stock inside the company?: Recent ZBIO insider activity includes MOULDER LEON O JR bought 60.00K, MOULDER LEON O JR bought 35.00K, MOULDER LEON O JR bought 25.00K, Lu Hongbo bought 3.77K, and Fairmount Funds Management LLC bought 150.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ZBIO?: Yes. Rallies tracks ZBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ZBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZBIO. It does not provide personalized investment advice.